Japanese-based researchers developed a new screening method that detects early stage colorectal cancer.
Japan-based Kobe University researchers teamed up with mart MRM technologies. and the National Cancer Center to develop a screening method that analyzes metabolites in blood.
Here's what you should know.
1. The group used gas chromatography-mass spectrometry and clinical metabolomic analysis to assess serum samples from colorectal patients and healthy subjects. The group identified four metabolite markers that could diagnose colorectal cancer.
They determined the approach was practical for existing tumors, but it wasn't sensitive enough to be a screening method.
2. The group created an approach that more accurately measured metabolites in blood plasma through the use of high-speed and sensitivity gas chromatography-mass spectrometry which employed Shimadzu's advanced scanning speed protocols and Smart MRM — Medication Risk Mitigation — technologies. Through this approach, they were able to identify eight biomarkers.
3. With the biomarkers, they created a diagnostic prediction model that exceeded 96 percent for sensitivity and specificity in cancer detection. The new model's sensitivity remained consistent with early-stage colorectal cancer patients.